Among 33 patients enrolled in the phase II HERACLES trial testing trastuzumab and lapatinib, a small molecule HER2/EGFR tyrosine kinase inhibitor, in patients with ERBB2 (HER2) amplified/KRAS wild-type CRC, the ORR was 30% with disease stabilization achieved in 70% of patients (8). The gene discussed is ERBB2; the disease is colorectal carcinoma.